ABSTRACT. Two TP53 gene polymorphisms at codon 47 (TP53 Pro47Ser) and at codon 72 (TP53 Arg72Pro) have been associated with susceptibility to various cancers. We carried out a case-control study and examined the genotype distribution of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms (SNPs), using a PCR-RFLP approach, to determine if these two SNPs are risk factors for colorectal cancer (CRC) development and to look for a possible correlation of these two SNPs with clinicopathological variables of CRC. We investigated the genotype distribution of these SNPs in 86 CRC cases in comparison with 160 healthy subjects in an ethnic Kashmiri population. TP53 Arg72Pro SNP genotype frequencies differed significantly (P = 0.000001) between the groups; the frequency of the Pro/Pro mutant was almost 20% in the general population. We also found significant association of the Pro/Pro mutant with tumor location, nodal status/higher tumor grade and bleeding per rectum/constipation. We conclude that Arg72Pro SNP is associated with susceptibility to developing CRC in this ethnic Kashmiri population.
INTRODUCTION
Colorectal cancer (CRC), being the most common cancer, is the major cause of mortality and morbidity worldwide, where there are nearly one million new cases of CRC diagnosed each year along with half a million deaths (Boyle and Leon, 2002) . The incidence of this malignancy shows considerable variation among racially or ethnically defined populations in multiracial/ethnic countries. Kashmir has been reported lately as being a high-incidence area of gastrointestinal (GIT) cancers (Mir et al., 2005; Murtaza et al., 2006) . In Kashmir Valley, CRC represents the third most common GIT cancer after esophageal and gastric (Sameer et al., 2009) as per Sher-I-Kashmir Institute of Medical Sciences (SKIMS) record registry, with almost 104 cases reported in 2009, as also reported previously by Shah and Jan (1990) .
TP53, a representative tumor suppressor, located on chromosome 17p13, is one of the most commonly mutated genes in all types of human cancer (Iacopetta, 2003; Whibley et al., 2009) . It is 19 kb in size and consists of 11 exons resulting in a transcript of 2629 bp and a protein of 393 amino acids (Bojesen and Nordestgaard, 2008) .
TP53 is responsible for the transcription of a site-specific DNA-binding protein and acts as a transcription factor of cell growth-regulator genes (Soussi and May, 1996) . In CRC, both germ line and somatic mutations of this gene have been reported by numerous studies up to a frequency of 45%. In half of all human cancers, the tumor suppressor p53 is damaged by somatic mutation in tumor cells (Iacopetta, 2003; Sameer et al., 2009) .
Genetic polymorphisms are an important cause of the predisposition to several human cancers. In the TP53 gene, several polymorphisms have been identified, both in non-coding and coding regions (Murphy, 2006; Bojesen and Nordestgaard, 2008; Costa et al., 2008; Whibley et al., 2009 ). Most of these polymorphisms are single-nucleotide polymorphisms (SNPs) affecting a single base. Within the coding regions of TP53, only two important polymorphisms are present, which alter the amino acid sequence of their products (Pietsch et al., 2006) ; these are located at codon 47 and codon 72 in exon 4. Codon 72 (Arg72Pro) is a frequent functional SNP that leads to an arginine-proline amino acid change, which has been reported by many authors (Thomas et al., 1999; Dumont et al., 2003) . Dumont et al. reported that the Arg72 allele, if in homozygous, has an apoptosis-inducing ability 15-fold higher compared to Pro72 allele. According to Leu et al. (2004) , this high apoptosis-inducing ability of the Arg72 allele is in part due to its mitochondrial location, which makes it possible for TP53 to have a direct interaction with pro-apoptotic BAK protein.
Studies on this SNP function were the basis for testing its impact on the risk and progression of tumors, where the less apoptotic allele Pro72 was associated with increased risk for development of tumors (Marin et al., 2000; Ignaszak-Szczepaniak et al., 2006; Toyama et al., 2007) . Codon 47 (Pro47Ser), is the second most common polymorphism in TP53 and leads to a substitution of proline with serine, first identified by Felley-Bosco et al. (1993) . The Ser47 polymorphic variant is very rare, with an allele frequency less than 5% in populations of African origin (Pietsch et al., 2006; Murphy, 2006; Whibley et al., 2009) . In a pioneer study by Li et al., in 2005 , it was found that the serine 47 polymorphic variant, which replaces the proline residue, necessary for recognition by proline-directed kinases, is a markedly poorer substrate for phosphorylation. Codon 47 encodes proline (CCG) in wild-type p53, but in a small subset of individuals it can encode serine (TCG).
In the present research, we conducted a case-control study and examined the genotype distribution of TP53 Pro47Ser and Arg72Pro SNPs, using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach, to evaluate its possible relevance in susceptibility to CRC and to study the correlation of these two SNPs with the clinicopathological variables of CRC cases.
MATERIAL AND METHODS

Study population
This study included 86 consecutive primary CRC patients. All CRC patients were recruited from the Department of Surgery, Sher-I-Kashmir Institute of Medical Sciences, from March 2008 to August 2009. Tumor types and stages were determined by two experienced pathologists. Blood samples of 160 age-and gender-matched cases with no signs of any malignancy were collected for controls. The mean age of both patient and control groups was 52 years old, and 56 patients and 104 controls were >50 years old or older. See Table 1 Data on all CRC patients were obtained from personal interviews with patients and/ or guardians, medical records and pathology reports. The data collected included gender, age, dwelling, tumor location, Dukes stage, lymph node status, pesticide exposure, and bleeding per rectum. All patients and/or guardians were informed about the study, and their consent to participate in this study was obtained on a predesigned questionnaire (available on request). The collection and use of tumor and blood samples for this study were previously approved by the appropriate Institutional Ethics Committee.
DNA extraction and polymerase chain reaction-restriction fragment length polymorphism
DNA extraction was performed using any one of the previously described techniques. Previously reported primers Katkoori et al., 2009) were used for the am-plification of the target regions of the TP53 Pro47Ser and Arg72Pro polymorphisms. Table 2 shows the primers and PCR product sizes. Table 2 . Primers for TP53 codon 47 and codon 72 polymorphism.
PCR was carried out in a final volume of 25 μL containing 50 ng genomic DNA template, 1X PCR buffer (Biotools) with 2 mM MgCl 2 , 0.4 μM of each primer (Genescript), 50 μM dNTPs (Biotools), and 0.5 U DNA polymerase (Biotools). For PCR amplification, the standard program was used as follows: one initial denaturation step at 94°C for 7 min, followed by 35 denaturation cycles of 30 s at 94°C, 30 s of annealing at 54°C, and 30 s of extension at 72°C, followed by a final elongation cycle at 72°C for 5 min.
For RFLP, the PCR products of TP53 Pro47Ser and Arg72Pro SNPs were digested with MspI (1 U at 37°C for 16 h) and BstUI (1 U at 37°C for 16 h) (Fermentas), respectively. In the case of TP53 Pro47Ser polymorphism Pro/Pro wild was identified by two bands (156/140 and 45 bp); Ser/Ser variant was identified by one band (201/185 bp), and heterozygous Pro/ Arg variant displayed three bands (201/185, 156/140, and 45 bp) (size divergences due to a 16-bp in/del intronic polymorphism near the TP53 SNP, as shown in Table 1 ). In the case of TP53 Arg72Pro polymorphism, the Arg/Arg wild produced two bands (160 and 119 bp); the Pro/Pro variant was identified by a single band (279 bp), and heterozygous Pro/Arg variant displayed three bands (279, 160, and 119 bp) (Figures 1 and 2) . 
TP53
Pro47Ser and Arg72Pro polymorphisms and colorectal cancer DNA fragments were electrophoresed through a 2-3% agarose gel for resolution. The genotypes of >20% of the samples were double blindly reassessed to confirm the results by two independent researchers. A positive control for each polymorphism was used for 50% of samples.
Statistical analysis
Observed frequencies of genotypes in CRC were compared to controls using chi-square or Fisher exact tests when expected frequencies were small. The chi-square test was used to verify whether genotype distributions were in Hardy-Weinberg equilibrium. Statistical significance was set at P < 0.05. Statistical analyses were performed with the PASW version 18 software.
RESULTS
A total of 86 CRC patients and 160 control subjects were included in this study. The patients comprised 49 males and 37 females (M/F ratio = 1.32), and the control subjects consisted of 88 males and 72 females (M/F ratio = 1.2). Mean age in patient and control groups was 52 years. No significant gender-or age-related differences were observed between the groups (P > 0.05). Furthermore, of the 86 confirmed cases of CRC, 81 cases were sporadic, 4 were familial adenomatous polyposis and one case was hereditary non-polyposis colorectal cancer. All but one case were adenocarcinoma and only one was squamous cell carcinoma of basal cell type. There were 59 rural and 27 urban cases.
Carcinoma of the colon occurred in 36 cases, and 50 patients had rectal cancer. There were 55 smokers and 31 non-smokers. See Tables 3-5 for further details. In this study, we found that the genotype frequencies in cases and controls were in Hardy-Weinberg equilibrium. Allele and genotype frequencies of TP53 Pro47Ser in cases and controls did not differ significantly (P = 0.166) but did in TP53 Arg72Pro (P = 0.000001). Fur-thermore, for TP53 Pro47Ser SNP, the frequencies of Pro/Pro and Pro/Ser genotypes among controls were 97.5 and 2.5%, while in cases these were 94.2 and 5.8%, respectively (P = 0.166) ( Table 3 ). For TP53 Arg72Pro SNP, frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes among controls were 40.6, 39.4 and 20.0%, while in cases these were 45.4, 43.0, and 11.6%, respectively (P = 0.000001).
The correlation of TP53 Arg72Pro polymorphic status with the clinicopathological characteristics was carefully analyzed. It was found that the Pro/Pro mutant status was significantly related to tumor location, nodal status/higher tumor grade and occurrence of bleeding per rectum/constipation, but not to other variables (Table 4) .
DISCUSSION
The incidences of polymorphism in genomic DNA, their susceptibility to genetic alterations, and the risk of tumor progression in patients with cancer can vary substantially between different racial groups (Perez et al., 2006; Bojesen and Nordestgaard, 2008; Katkoori et al., 2009) . Although most polymorphisms are functionally neutral, some affect regulation of gene expression or the function of the coded protein (Costa et al., 2008) . Several studies have been carried out on the association of TP53 polymorphism with increased risk for various cancers (Sjalander et al., 1996; Thomas et al., 1999; Lee et al., 2000; Hiyama et al., 2002; Irarrazabal et al., 2003; Zhu et al., 2007) . However, in CRC the data available on the TP53 polymorphic status are somewhat ambiguous, where several studies found no association (Sjalander et al., 1995; Sayhan et al., 2001; Hamajima et al., 2002; Schneider-Stock et al., 2004) . Other authors reported an inverse association (Perez et al., 2006) , whereas another study indicated a positive association (Gemignani et al., 2004) .
In this study, we assessed the two most common SNPs of TP53, Pro47Ser and Arg72Pro, in an ethnic Kashmiri population for the first time, since the role of TP53 polymorphism in relation to CRC risk had not yet been reported from this part of the world.
In the case of TP53 Pro47Ser SNP, we found that Ser/Ser frequency was 2.5% in controls, whereas 5.8% in cases, clearly showing a non-significant association of this SNP with CRC predisposition. This observation was in contrast to the previous study, showing a significant association between the mutant Ser47 phenotype and cancer risk (Felley-Bosco et al., 1993) . This effect is because the mutant Ser47 phenotype has a decreased capacity to induce apoptosis, to transactivate two p53 target genes, p53AIP1 and PUMA, and to bind to MAPK1 protein as compared with the wild-type Pro47 phenotype (Li et al., 2005; Murphy, 2006; Katkoori et al., 2009 ).
In the case of TP53 Arg72Pro SNP, we found that wild-type Arg/Arg frequency was 40.6% in controls whereas 11.6% in cases, and mutant Pro-Pro frequency was 20.0% in control whereas 45.4% in cases. Thus, Pro/Pro mutant phenotype shows a significant association with colorectal tumor development (P = 0.000001).
Codon 72 polymorphism of TP53 is located within a proline-rich region of the p53 protein and is functionally important in growth suppression and apoptosis (Katkoori et al., 2009) . Furthermore, it has been shown that the Arg72 form of p53 has a 15-fold greater capacity to induce apoptosis compared to Pro72, and that this is due to more efficient localization of the Arg72 form to the mitochondria (Thomas et al., 1999; Dumont et al., 2003; Murphy, 2006) . Moreover, several earlier studies have reported a significant association between Pro/Pro mutant phenotype and the risk of developing colorectal cancers (Sjalander et al., 1995; Gemignani et al., 2004; Zhu et al., 2007 Zhu et al., , 2008 Katkoori et al., 2009 ). Thus, our findings are in tune with these studies. Another remarkable fact that has arisen from this study is that our Kashmiri population has a significantly greater Pro/Pro allele frequency than Arg/Arg. This may be due to the fact that we reside at high altitudes under low-oxygen conditions and environmental extremes, especially high exposure to UV rays. This observation is similar to that in previously reported studies (Bojesen and Nordestgaard, 2008; Katkoori et al., 2009) , where a high Pro/Pro mutant phenotype was found to be a race-specific prognostic molecular marker in CRC, especially in populations challenged by the environment; this is because Pro72 allele has been found to be a better protector against sunlightinduced diseases (Beckman et al., 1994; Zehbe et al., 1998; Katkoori et al., 2009) . Furthermore, as the polymorphism is also affected by lifestyle, diet and/or environmental exposure, which vary according to race and ethnicity (Devesa and Chow, 1993; Gapstur et al., 1994) , we suggest that as our population is exposed to a special set of environmental and dietary risks, which include the consumption of sun-dried and smoked fish and meat, dried and pickled vegetables, red chilli, hakh (a leafy vegetable of the Brassica family), hot noon chai (salted tea), and hukka (water pipe) smoke (Mir et al., 2005) . As previously reported, the etiology and incidence of various GIT cancers in this population has been attributed to probable exposure to nitroso compounds, amines and nitrates, reported to be present in local foodstuffs, most of which have been shown to contain important irritants and carcinogens (Siddiqi et al., 1992; Murtaza et al., 2006) . This might have caused the evolutionary preferential selection of Pro72 over Arg72 to deal with the challenge in a better way.
Furthermore, we also found in this study a significant association between the Pro/Pro mutant status and tumor location, nodal status/higher tumor grade and bleeding per rectum/ constipation, but not with other clinicopathological variables (Table 4) . These results were similar as previously reported by various authors (Sjalander et al., 1995; Schneider-Stock et al., 2004; Lung et al., 2004; Zhu et al., 2007 Zhu et al., , 2008 Katkoori et al., 2009) .
Hence, in this study, which was carried out for the first time in Kashmir Valley, we observed a significant correlation between the Pro/Pro mutant status and tumor location, nodal status/higher tumor grade and bleeding per rectum/constipation, together with the preferential selection of the Pro/Pro mutant allele (frequency = 20%) in this ethnic Kashmiri population. However, this correlation needs to be authenticated in a large sample study in the future, so as to help in the better discernment of racial differences and in determining the aggressiveness of colorectal cancer, as suggested by Katkoori et al. (2009) .
